Journal
ONCOTARGETS AND THERAPY
Volume 14, Issue -, Pages 2149-2161Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S297272
Keywords
CD8; CD39; T cells; anti-tumor cytotoxicity; bladder cancer; immunotherapy; TILs; immune checkpoint
Categories
Funding
- National Natural Science Foundation of China [81772727, 81772710]
- China Postdoctoral Foundation [2016M591831]
- Nanjing Science and Technology Development Project [YKK16073]
Ask authors/readers for more resources
The high expression of CD39 in BLCA patients is significantly associated with advanced tumor stage and worse survival rate, while CD8+CD39+ T cells exhibit stronger tumor-killing effect and produce higher level of IFN-gamma compared to other T cell populations.
Introduction: Although immunotherapy works well in parts of patients with bladder cancer (BLCA), its overall response rate of anti-PD-1 inhibitors remains unsatisfactory. Besides, growing evidence shows that tumor-infiltrating lymphocytes (TILs) immunotherapy has demonstrated excellent efficacy in various cancers. Considering the huge heterogeneity and low overall survival rate of BLCA, it is urgent to explore the new immune checkpoints (ICs) or TILs therapy to improve the survival prognosis for BLCA patients. Materials and Methods: The public bioinformatics databases were used to explore the prognostic value of 5 potential ICs targets (TIM-3, LAG-3, OX40, 4-1BB and CD39). A total of 46 BLCA patients undergoing surgical treatment at our hospital from May 2020 to October 2020 were enrolled in this study. The expressions of PD-1, TIM-3, LAG-3, OX40, 4-1BB, and CD39 in T cells of BLCA patients were explored by flow cytometry, and the correlation between different subgroups of T cells and clinicopathological parameters was analyzed. Besides, the mouse CD4+CD39+ T cells, CD4+CD39- T cells, CD8+CD39+ T cells, and CD8+CD39- T cells were sorted and co-cultured with MB49 bladder cancer cell lines in vitro to investigate the potential biomarker of tumor-reactive TILs. Results: Public bioinformatics databases analyses show that only the high expression of CD39 was significantly associated with advanced tumor stage (P < 0.001) and tend to result in a worse survival rate. In our study, the elevated expression of CD39 in CD4+/CD8+ T cells were significantly associated with the pathological T stage (pT <2, P = 0.041) and papillary tumor (P = 0.038). Moreover, the CD8+CD39+ T cells showed a stronger tumorkilling effect and produced a higher level of IFN-gamma than other T cell populations. Conclusion: CD39 may be a potential prognostic marker in BLCA, and CD8+CD39+ T cells may be selected as tumor-reactive and killing T cells for TILs therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available